Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512221 · ClinicalTrials.gov registry record · NA
Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics
A NA study of GBAT+Individual and GBAT+Engagement Booster, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05512221: Completed NA study of GBAT+Individual and GBAT+Engagement Booster, sponsored by Rutgers, The State University of New Jersey.
NCT05512221 is a NA study of GBAT+Individual and GBAT+Engagement Booster that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05512221, a NA study of GBAT+Individual and GBAT+Engagement Booster, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to build upon an earlier study that evaluated the use of a 10-week transdiagnostic Group Behavioral Activation Therapy (GBAT), a telehealth delivered intervention, as a cost effective and accessible way to treat symptoms of anxiety and depression in autistic adults. The current study will pilot and compare relative feasibility, acceptability, and preliminary efficacy of three adapted GBAT groups and a Watchful Waiting (WW) group. The three groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions), GBAT+Engagement Booster (GBAT+E; supplemental materials), and GBAT+Both (GBAT+IE individual sessions and supplemental materials).
Primary Outcome
The CGI-S score provides a global rating of baseline severity ranging from 1 (not at all ill) to 7 (extremely ill), while the CGI-I provides a global rating of clinical improvement ranging from 1 (Very Much Improved) to 7 (Very Much Worse). The IE will provide a baseline CGI ratings for each patient at pretreatment and posttreatment.
Conditions Studied
Interventions
- OTHER GBAT+I, GBAT+E - Phase I
- OTHER Watchful Waiting and Groups - Phase 2
- OTHER GBAT+IE
Study Locations (1)
New Jersey
- Rutgers University - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2024-07-01 |
| Phase | NA |
What the finished NCT05512221 record still lists
NCT05512221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with GBAT+Individual appearing as the primary indexed condition, and to 3 interventions - of which GBAT+I, GBAT+E - Phase I is the first listed.
NCT05512221 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05512221 about?
NCT05512221 is a clinical study titled "Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics". The purpose of this study is to build upon an earlier study that evaluated the use of a 10-week transdiagnostic Group Behavioral Activation Therapy (GBAT), a telehealth delivered intervention, as a cost effective and accessible way to treat symptoms of anxiety and depression in autistic adults. The ...
What is the current status of trial NCT05512221?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2022-09-23. Estimated completion is 2024-07-01.
What conditions does trial NCT05512221 study?
This clinical trial studies the following conditions: GBAT+Individual, GBAT+Engagement Booster, GBAT+Both.
What interventions are being tested in trial NCT05512221?
The interventions under investigation include: GBAT+I, GBAT+E - Phase I (OTHER), Watchful Waiting and Groups - Phase 2 (OTHER), GBAT+IE (OTHER).
Who is sponsoring clinical trial NCT05512221?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512221 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05512221's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI